109.00
+4.95%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Spyre Therapeutics
From its filings with the US Securities and Exchange Commission
Spyre Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SYRE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $155.2m. At that date it held total assets of $777.8m and shareholders' equity of $715.2m.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.
Our next-generation monotherapy antibody candidates targeting α4β7, TL1A, and IL-23 are engineered to match or exceed the potency of comparator first generation molecules (Figure 1), maintain selectivity, incorporate Fc domain modifications called YTE substitutions in order to increase pharmacokinetic half-life (Figure 2), and are formulated as high-concentration, citrate-free formulations. Combined, these attributes have the potential to enable quarterly or twice annual subcutaneous ("SC") maintenance dosing, and have upside potential to increase or accelerate efficacy via increasing PK exposures, based on published exposure-response or dose-response relationships for each mechanism in IBD.
SPY001 PK simulation based on PK data as of 03/19/2025 cutoff; SPY002 PK simulation based on PK data from 5/31/2025 cutoff; SPY003 PK simulation based on PK data from 9/15/2025 cutoff. Vedolizumab, Afimkibart, and Risankizumab simulations based on published data (Rosario, M, et. al. (2015); Danese, Silvio, et al. (2024); Thakre, Neha et. al. (2024)); no head-to-head clinical trials have been conducted. Concept image of drug delivery device shown for illustrative purposes only.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Apr 2016
- Employees
- 102
- Website
- spyre.com ↗
- Head office
- 221 CRESCENT STREET, WALTHAM, MA, 02453
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Jeffrey AlbersIndependent Chairman of the Board$437,575
- Dr. Cameron TurtleChief Executive Officer, Director, since 2023$7.0m
- Mr. Scott BurrowsChief Financial Officer$2.2m
- Dr. Sheldon SloanChief Medical Officer$9.4m
- Ms. Heidy King-JonesChief Legal Officer, Corporate Secretary$6.6m
- Mr. Mark MckennaDirector$874,717
- Mr. Peter HarwinIndependent Director$401,109
- Dr. Michael HendersonIndependent Director$403,221
- Mr. Tomas KiselakIndependent Director$400,721
- Dr. Sandra MilliganIndependent Director$736,957
- Ms. Laurie StelzerIndependent Director$418,221
- Mr. Eric McintyreInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 49
- Social
- 55
- Governance
- 34
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Spyre Therapeutics' SPY001 targets α4β7 integrin for inflammatory bowel disease treatment.
- SPY002 focuses on TL1A for highly selective inflammatory bowel disease therapy.
- SPY003 targets IL-23 p19 subunit with potent and selective inflammatory bowel disease approach.
Weaknesses
- Spyre Therapeutics has only 102 employees in the US Biotechnology sector.
- The company's pipeline includes only four product candidates SPY001 to SPY004.
- Spyre Therapeutics' IPO was in 2016, indicating limited recent market presence.
Opportunities
- The US Biotechnology sector shows growth potential for inflammatory bowel disease treatments.
- SPY001 and SPY002 could expand into new markets for IBD therapies.
- SPY003's IL-23 targeting approach may attract partnerships in Health Care.
Threats
- Biotechnology companies face intense competition in the US Health Care sector.
- Regulatory challenges may delay SPY001 and SPY002 development timelines.
- Market volatility could impact Spyre Therapeutics' IPO-based funding strategy.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.